×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Brain

Feature Video
Watch a video about Chad, a patient using Optune.
Learn how Chad manages his treatment while enjoying his favorite activities.
Samira Rajabi
Those of us who have suffered often fear what can go wrong with them. But the more we know our bodies, the more we can love them and ourselves.
David Reardon, M.D.

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
Jeannine Walston
Both oncologists and primary care physicians do not provide adequate care to fully address cancer survivorship needs. Learn about why and solutions for people in their cancer journey.
David Reardon, M.D.
David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, offers advice for patients who have recently been diagnosed with glioblastoma (GBM).
Brielle Urciuoli
In early 2015, Zika outbreaks caused widespread panic in many parts of North and South America. However, now researchers are exploring the possibility of putting the virus to good use: fighting glioblastoma multiforme (GBM), the most deadly type of brain cancer.
Jason Harris
The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.
 
Samira Rajabi
Every six months, I get an MRI to check for recurrence or growth of my brain tumor. This is one of those times. To prepare for tomorrow, I try to remember not to forgo today.
Angelica Welch
A phase 2 trial – which is still enrolling patients – is investigating multiple targeted agents for the treatment of patients with glioblastoma (GBM).
Samira Rajabi
Moving with a health problem comes with the logistical challenge of finding resources in a new place which is a task conquered through patience, kindness and a lot of organization.
Thomas Keenan
The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.  
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable